# Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

> **NCT06601296** · PHASE2 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma ( mRCC)
- OligoProgressive Metastatic Disease

## Interventions

- **DRUG:** IMSA101

## Key facts

- **NCT ID:** NCT06601296
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06601296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06601296, "Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06601296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*